Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HM16390 · 1 trial · 1 indication
To evaluate safety and tolerability of HM16390 as a single agent and in combination with pembrolizumab
To evaluate safety and tolerability of HM16390 as a single agent, and in combination with pembrolizumab
| Arm | Type | Description |
|---|---|---|
| HM16390 | EXPERIMENTAL | HM16390 Monotherapy |
| HM16390 + pembrolizumab | EXPERIMENTAL | HM16390 in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| HM16390 | DRUG | HM16390 will be administered subcutaneously using syringes on Day 1 of every 3-week treatment cycle |
| pembrolizumab | DRUG | Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle |
Key Inclusion Criteria: * Have a histologically and/or cytologically confirmed advanced or metastatic solid tumor and have failed or are intolerant to standard therapy with clinical benefit. * Patients in the Dose-Escalation Part must have evaluable or measurable disease at baseline and the patient...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
HM16390 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development, where it is being studied alone or in combination with pembrolizumab in patients with these types of cancer.
HM16390 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial of HM16390 in patients with advanced or metastatic solid tumors.
HM16390 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is a dose escalation and expansion study evaluating HM16390 alone or with pembrolizumab in advanced or metastatic solid tumors.
HM16390 is being studied in a Phase 1 clinical trial with the identifier NCT06724016. This trial is a dose escalation and expansion study of HM16390 alone or with pembrolizumab in patients with advanced or metastatic solid tumors. The trial is currently recruiting participants in the United States and South Korea.
Yes, HM16390 is being studied both alone and in combination with pembrolizumab in a Phase 1 clinical trial for advanced or metastatic solid tumors. The trial is designed to evaluate the safety and efficacy of HM16390 in these settings, with a planned enrollment of 292 participants.